Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

OKYO vs SGHT vs LNTH vs NVCR vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OKYO
OKYO Pharma Limited

Biotechnology

HealthcareNASDAQ • GB
Market Cap$66M
5Y Perf.-20.5%
SGHT
Sight Sciences, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$293M
5Y Perf.-37.4%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$6.06B
5Y Perf.+35.8%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.04B
5Y Perf.-77.7%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$97.62B
5Y Perf.-24.0%

OKYO vs SGHT vs LNTH vs NVCR vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OKYO logoOKYO
SGHT logoSGHT
LNTH logoLNTH
NVCR logoNVCR
MDT logoMDT
IndustryBiotechnologyMedical - DevicesDrug Manufacturers - Specialty & GenericMedical - Instruments & SuppliesMedical - Devices
Market Cap$66M$293M$6.06B$2.04B$97.62B
Revenue (TTM)$0.00$80M$1.55B$674M$35.48B
Net Income (TTM)$-5M$-37M$279M$-173M$4.61B
Gross Margin86.2%60.5%75.2%61.9%
Operating Margin-44.8%18.8%-27.2%17.9%
Forward P/E17.7x13.8x
Total Debt$0.00$41M$738K$290M$28.52B
Cash & Equiv.$2M$92M$359M$103M$2.22B

OKYO vs SGHT vs LNTH vs NVCR vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OKYO
SGHT
LNTH
NVCR
MDT
StockMay 22May 26Return
OKYO Pharma Limited (OKYO)10079.5-20.5%
Sight Sciences, Inc. (SGHT)10062.6-37.4%
Lantheus Holdings, … (LNTH)100135.8+35.8%
NovoCure Limited (NVCR)10022.3-77.7%
Medtronic plc (MDT)10076.0-24.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: OKYO vs SGHT vs LNTH vs NVCR vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Sight Sciences, Inc. is the stronger pick specifically for recent price momentum and sentiment. LNTH and NVCR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
OKYO
OKYO Pharma Limited
The Healthcare Pick

Among these 5 stocks, OKYO doesn't own a clear edge in any measured category.

Best for: healthcare exposure
SGHT
Sight Sciences, Inc.
The Momentum Pick

SGHT is the #2 pick in this set and the best alternative if momentum is your priority.

  • +77.6% vs MDT's -5.5%
Best for: momentum
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.

  • 42.9% 10Y total return vs MDT's 24.3%
  • Lower volatility, beta 0.45, Low D/E 0.1%, current ratio 2.70x
  • 18.0% margin vs SGHT's -46.8%
Best for: long-term compounding and sleep-well-at-night
NVCR
NovoCure Limited
The Growth Play

NVCR is the clearest fit if your priority is growth exposure.

  • Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
  • 8.3% revenue growth vs OKYO's -11K%
Best for: growth exposure
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 36 yrs, beta 0.42, yield 3.7%
  • Beta 0.42, yield 3.7%, current ratio 1.85x
  • Better valuation composite
  • Beta 0.42 vs SGHT's 2.41, lower leverage
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthNVCR logoNVCR8.3% revenue growth vs OKYO's -11K%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsLNTH logoLNTH18.0% margin vs SGHT's -46.8%
Stability / SafetyMDT logoMDTBeta 0.42 vs SGHT's 2.41, lower leverage
DividendsMDT logoMDT3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)SGHT logoSGHT+77.6% vs MDT's -5.5%
Efficiency (ROA)MDT logoMDT175.8% ROA vs OKYO's -128.4%

OKYO vs SGHT vs LNTH vs NVCR vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OKYOOKYO Pharma Limited

Segment breakdown not available.

SGHTSight Sciences, Inc.
FY 2025
Surgical Glaucoma
97.9%$76M
Dry Eye
2.1%$2M
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
NVCRNovoCure Limited

Segment breakdown not available.

MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

OKYO vs SGHT vs LNTH vs NVCR vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

LNTH leads this category, winning 3 of 6 comparable metrics.

MDT and OKYO operate at a comparable scale, with $35.5B and $0 in trailing revenue. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to SGHT's -46.8%. On growth, SGHT holds the edge at +12.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOKYO logoOKYOOKYO Pharma Limit…SGHT logoSGHTSight Sciences, I…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
RevenueTrailing 12 months$0$80M$1.5B$674M$35.5B
EBITDAEarnings before interest/tax-$4M-$35M$347M-$165M$9.4B
Net IncomeAfter-tax profit-$5M-$37M$279M-$173M$4.6B
Free Cash FlowCash after capex-$2M-$25M$372M-$48M$5.4B
Gross MarginGross profit ÷ Revenue+86.2%+60.5%+75.2%+61.9%
Operating MarginEBIT ÷ Revenue-44.8%+18.8%-27.2%+17.9%
Net MarginNet income ÷ Revenue-46.8%+18.0%-25.7%+13.0%
FCF MarginFCF ÷ Revenue-31.9%+24.0%-7.1%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+12.5%+1.2%+12.3%+8.8%
EPS Growth (YoY)Latest quarter vs prior year+83.3%+14.3%+76.5%-100.0%-11.9%
LNTH leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 4 of 6 comparable metrics.

At 21.1x trailing earnings, MDT trades at a 23% valuation discount to LNTH's 27.3x P/E. On an enterprise value basis, MDT's 14.1x EV/EBITDA is more attractive than LNTH's 15.0x.

MetricOKYO logoOKYOOKYO Pharma Limit…SGHT logoSGHTSight Sciences, I…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Market CapShares × price$66M$293M$6.1B$2.0B$97.6B
Enterprise ValueMkt cap + debt − cash$65M$242M$5.7B$2.2B$123.9B
Trailing P/EPrice ÷ TTM EPS-13.58x-7.27x27.29x-14.66x21.09x
Forward P/EPrice ÷ next-FY EPS est.17.70x13.80x
PEG RatioP/E ÷ EPS growth rate35.17x
EV / EBITDAEnterprise value multiple14.96x14.06x
Price / SalesMarket cap ÷ Revenue3.78x3.93x3.11x2.91x
Price / BookPrice ÷ Book value/share4.39x5.84x5.86x2.04x
Price / FCFMarket cap ÷ FCF17.11x18.83x
MDT leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 6 of 9 comparable metrics.

LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-59 for SGHT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs OKYO's 3/9, reflecting solid financial health.

MetricOKYO logoOKYOOKYO Pharma Limit…SGHT logoSGHTSight Sciences, I…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
ROE (TTM)Return on equity-59.1%+24.3%-50.8%+9.4%
ROA (TTM)Return on assets-128.4%-32.2%+12.4%-16.5%+175.8%
ROICReturn on invested capital-2.7%+30.6%-16.4%+6.0%
ROCEReturn on capital employed-32.0%+17.1%-28.9%+7.5%
Piotroski ScoreFundamental quality 0–935556
Debt / EquityFinancial leverage0.64x0.00x0.85x0.59x
Net DebtTotal debt minus cash-$2M-$51M-$358M$187M$26.3B
Cash & Equiv.Liquid assets$2M$92M$359M$103M$2.2B
Total DebtShort + long-term debt$0$41M$738,000$290M$28.5B
Interest CoverageEBIT ÷ Interest expense-8.03x-14.04x15.83x-96.80x9.08x
LNTH leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LNTH leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, SGHT leads with a +77.6% total return vs MDT's -5.5%. The 3-year compound annual growth rate (CAGR) favors LNTH at -0.6% vs NVCR's -36.4% — a key indicator of consistent wealth creation.

MetricOKYO logoOKYOOKYO Pharma Limit…SGHT logoSGHTSight Sciences, I…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
YTD ReturnYear-to-date-26.9%-28.1%+38.3%+36.4%-20.0%
1-Year ReturnPast 12 months+10.1%+77.6%+15.7%+2.6%-5.5%
3-Year ReturnCumulative with dividends-23.5%-48.9%-1.9%-74.2%-6.3%
5-Year ReturnCumulative with dividends-55.0%-83.9%+338.1%-90.2%-29.2%
10-Year ReturnCumulative with dividends-55.0%-83.9%+4289.6%+38.5%+24.3%
CAGR (3Y)Annualised 3-year return-8.5%-20.0%-0.6%-36.4%-2.1%
LNTH leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than SGHT's 2.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs OKYO's 48.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOKYO logoOKYOOKYO Pharma Limit…SGHT logoSGHTSight Sciences, I…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5000.98x2.41x0.45x2.15x0.42x
52-Week HighHighest price in past year$3.35$9.24$94.86$20.06$106.33
52-Week LowLowest price in past year$1.32$2.81$47.25$9.82$75.91
% of 52W HighCurrent price vs 52-week peak+48.7%+58.3%+98.1%+89.2%+71.6%
RSI (14)Momentum oscillator 0–10050.270.269.970.929.2
Avg Volume (50D)Average daily shares traded93K359K872K1.4M7.9M
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SGHT as "Buy", LNTH as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 87.3% upside for NVCR (target: $34) vs 6.7% for LNTH (target: $99). MDT is the only dividend payer here at 3.65% yield — a key consideration for income-focused portfolios.

MetricOKYO logoOKYOOKYO Pharma Limit…SGHT logoSGHTSight Sciences, I…LNTH logoLNTHLantheus Holdings…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$9.67$99.25$33.50$109.50
# AnalystsCovering analysts9171549
Dividend YieldAnnual dividend ÷ price+3.7%
Dividend StreakConsecutive years of raises1036
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+5.0%0.0%+3.3%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

LNTH leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallLantheus Holdings, Inc. (LNTH)Leads 3 of 6 categories
Loading custom metrics...

OKYO vs SGHT vs LNTH vs NVCR vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OKYO or SGHT or LNTH or NVCR or MDT a better buy right now?

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Sight Sciences, Inc. (SGHT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OKYO or SGHT or LNTH or NVCR or MDT?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Lantheus Holdings, Inc. at 27. 3x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x.

03

Which is the better long-term investment — OKYO or SGHT or LNTH or NVCR or MDT?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +338. 1%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus SGHT's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OKYO or SGHT or LNTH or NVCR or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

42β versus Sight Sciences, Inc. 's 2. 41β — meaning SGHT is approximately 467% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — OKYO or SGHT or LNTH or NVCR or MDT?

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OKYO or SGHT or LNTH or NVCR or MDT?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -49. 7% for Sight Sciences, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -48. 0% for SGHT. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OKYO or SGHT or LNTH or NVCR or MDT more undervalued right now?

On forward earnings alone, Medtronic plc (MDT) trades at 13.

8x forward P/E versus 17. 7x for Lantheus Holdings, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

08

Which pays a better dividend — OKYO or SGHT or LNTH or NVCR or MDT?

In this comparison, MDT (3.

7% yield) pays a dividend. OKYO, SGHT, LNTH, NVCR do not pay a meaningful dividend and should not be held primarily for income.

09

Is OKYO or SGHT or LNTH or NVCR or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). Sight Sciences, Inc. (SGHT) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, SGHT: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OKYO and SGHT and LNTH and NVCR and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OKYO is a small-cap quality compounder stock; SGHT is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while OKYO, SGHT, LNTH, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OKYO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

SGHT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 51%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.